|Molecular biologists find niche as new technologies are adapted to the animal health market.|
But this situation could be changing. A growing number of vaccines for cats, dogs, and fish are based on recombinant DNA techniques. New diagnostic tests for these animals also rely on biotechnology. These emerging products offer molecular biologists-traditionally the mavens of human health research-a new niche.
"Biotech is now having as profound an impact on animal health as human health," contends Timothy Cronin, senior vice president of animal health research at New York-based Pfizer Inc. "The real opportunities today are in companion animals [dogs and cats]." Cronin says the knowledge needed to enter this line...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?